Mercados españoles cerrados

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
80,07+0,84 (+1,06%)
Al cierre: 04:00PM EDT
80,06 -0,01 (-0,01%)
Después del cierre: 05:06PM EDT

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
44 20 3749 5000
https://www.astrazeneca.com

Sector(es)Healthcare
SectorDrug Manufacturers - General
Empleados a tiempo completo89.900

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Pascal Soriot D.V.M., M.B.A.CEO & Executive Director5,81MN/A1959
Dr. Aradhana Sarin M.D.CFO & Executive Director3,2MN/A1974
Ms. Pam P. ChengEVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. BoardN/AN/A1970
Mr. Andrew P. BarnettHead of Investor RelationsN/AN/AN/A
Mr. Jeffrey PottCHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory BoardN/AN/AN/A
Gonzalo VinaHead of Global Media RelationsN/AN/AN/A
Dr. Ruud Dobber Ph.D.Executive Vice-President of BioPharmaceuticals Business UnitN/AN/AN/A
Dr. Susan Mary Galbraith M.D., Ph.D.Executive Vice President of Oncology Research & DevelopmentN/AN/A1966
Mr. Leon WangExecutive VP of International & China PresidentN/AN/AN/A
Ms. Iskra ReicExecutive Vice-President of Vaccines & Immune TherapiesN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Gobierno corporativo

El ISS Governance QualityScore de AstraZeneca PLC, a día 1 de junio de 2024, es 9. Las puntuaciones base son Auditoría: 5; Tablero: 3; Derechos de los accionistas: 9; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.